DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial

By on    Pharma Industry News  

DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial

Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate, in wet age-related macular degeneration (wet AMD). The DAZZLE trial (also called KSI-CL-102) is designed to assess the safety and efficacy of KSI-301 in AMD patients who are treatment-naïve. […]

FDA approves Dompé’s Oxervate for rare eye disease treatment

By on    Pharma Industry News  

FDA approves Dompé’s Oxervate for rare eye disease treatment

Dompé farmaceutici, an Italian pharmaceutical company, has achieved a milestone with the U.S. Food and Drug Administration (FDA) approval of Oxervate (cenegermin) eye drops for the treatment of neurotrophic keratitis, a rare degenerative eye disease. This approval marks Oxervate as the first FDA-sanctioned drug specifically for this condition. Details on Neurotrophic Keratitis: Neurotrophic keratitis is […]